U.S. Secretary of State Hillary Clinton on Tuesday visited officials in South Africa and discussed the response to HIV/AIDS, the Associated Press/Huffington Post reports. Speaking with Foreign Minister Maite Nkoana-Mashabane “in the second cabinet-level strategic dialogue between the two nations,” Clinton said “that global efforts to stop the virus ‘have saved hundreds of thousands of lives,’” the news service writes. “In South Africa, 5.7 million people — 17.8 percent of the population — have tested positive for HIV,” and PEPFAR “has spent $3.2 billion on antiretroviral drugs and HIV prevention programs in [the country] since 2004,” according to the AP.
Treatment and Prevention Strategies
“Malawi on Monday launched a week-long campaign to test 250,000 people for HIV in what health authorities called a crucial intervention in a country ravaged by AIDS,” Agence France-Presse reports. “The week would give Malawians ‘a chance to access antiretroviral therapy if found HIV positive,’ said Deputy Health Minister Halima Daudi at the launch,” the news service writes, noting, “People will take tests in 810 sites in the southern African nation’s 28 districts.” Approximately 10 percent of Malawi’s 14 million residents are living with HIV, according to AFP (8/6).
Dominican Republic Establishes Commission To Examine Implications Of Including ART In Country Health Plan
“The Dominican Republic is one step closer to ensuring that all people living with HIV access treatment,” UNAIDS reports in an article on its webpage, adding, “The country’s National Social Security Council has established a commission to look into the technical, financial and operational implications of including antiretroviral therapy (ART) in the Basic Health Plan.” According to the article, “[t]he establishment of the commission comes after a financial feasibility study about covering people living with HIV under the country’s family health insurance,” and “[t]he newly-established commission — whose membership includes several national health system offices in addition to regional and global partners such as PAHO and UNAIDS — is set to complete its work during the last quarter of 2012” (8/23).
“Over the 30 years of the AIDS epidemic, the disease has had a profound impact on every country in the world,” and “in each country, that impact is experienced a different way,” Vivek Anand, CEO of the Humsafar Trust, and Kenneth Mayer, medical research director of Fenway Health and co-director of the Fenway Institute, write in this post in Huffington Post’s “Gay Voices” blog. “But one reality remains: In nearly every country, HIV rates are disproportionately high in gay and bisexual men, as well as men who have sex with men (MSM) who do not identify as either,” they continue, adding, “The full scope of the epidemic simply cannot be addressed until we recognize that there is no country in the world where we can overlook the MSM population.”
The XIX International AIDS Conference (AIDS 2012) that took place last week in Washington, D.C., “ignited momentum to shift from ‘fighting AIDS’ to ‘ending AIDS,’” Mohga Kamal-Yanni, senior health adviser at Oxfam International, and Urvarshi Rajcoomer, policy and advocacy adviser at Oxfam in South Africa, write in a Mail & Guardian opinion piece. “Oxfam believes investing in health systems such as infrastructure and health worker, drug supply chain and health information systems, is a critical prerequisite to ending AIDS,” they write. However, “to make this a reality,” pharmaceutical companies, donor governments, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the World Bank “must now do their part,” they continue.
In this post in Huffington Post’s “Impact” blog, Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, examines “the success of U.S. efforts to promote better global health through support for [PEPFAR] and the Global Fund to Fight AIDS, Tuberculosis and Malaria.” She highlights U.S. Secretary of State Hillary Clinton’s recent trip to Africa, writing that Clinton’s “encouraging words” at the Reach Out Mbuya health center in Uganda reinforced U.S. commitment to an AIDS-free generation. She notes both PEPFAR and the Global Fund have supported the center and adds that “through hundreds of similar local programs all over the world, the Global Fund provides treatment to 3.6 million people who are HIV-positive.”
In this post in BMJ’s “Yankee Doodling,” Douglas Kamerow, chief scientist at RTI International and an associate editor for the journal, reflects on the possibility of achieving an AIDS-free generation “if somehow we succeeded in getting all HIV positive people in the world identified and under long term treatment.” He writes that while there has been “astonishing progress against AIDS,” “two concerns immediately arise: the magnitude of the work remaining to find and continuously treat all those infected, and the confusion between that treatment (even if it is somehow universally successful) and actual eradication of the disease.” He concludes, “It is a rosy scenario, but even if it came true it still would not spell the end of the HIV story,” because “[w]e have no vaccine, and the virus keeps mutating” (8/14).
In this post in Huffington Post’s “Healthy Living” blog, John-Manuel Andriote, a journalist and author living with HIV, writes, “For all of us living with HIV infection — Oct. 27 will mark seven years since my own diagnosis — the question we face daily, hopefully more consciously and deliberately than most, is how shall we live, knowing as we do that we will most assuredly die one day?” Reflecting on the XIX International AIDS Conference (AIDS 2012) that took place in Washington last month, he continues, “An AIDS-free generation is certainly a worthy goal,” but “even if tens of billions of additional dollars are allocated to address HIV/AIDS, even if the Republicans don’t succeed in inflicting their Darwinian ‘survival of the fittest’ upon the nation and the world, the question will continue to be what it has been for 31 years … Will we have the political will to end AIDS?”
In an opinion piece in the Guardian’s “Comment is Free” blog, Dean Baker, co-director of the Center for Economic and Policy Research, discusses potential policies contained within the “Trans-Pacific Partnership Agreement (TPP), a pact that the United States is negotiating with Australia, Canada, Japan and eight other countries in the Pacific region.” However, “[a]t this point, it’s not really possible to discuss the merits of the TPP since the governments are keeping the proposed text a secret from the public,” he says. Noting “[a] few items that have been leaked give us some insight as to the direction of this pact,” he discusses how the “pharmaceutical industry is … likely to be a big gainer” from the TPP if the pact includes “stronger and longer patent protection and also increased use of ‘data exclusivity.’”
Advocacy Groups Warn Trans-Pacific Partnership Could Affect Access To Low-Cost Medications, Bloomberg Reports
Bloomberg Businessweek examines how ongoing trade negotiations related to the Trans-Pacific Partnership could affect access to quality low-cost medications, including antiretrovirals, in low- and middle-income countries. “Protecting the patents of drug makers … as part of the Trans-Pacific Partnership has drawn criticism from groups such as Doctors Without Borders and Public Citizen,” and “[t]he proposed accord has also spurred calls from U.S. lawmakers for greater transparency about the negotiations,” the news service writes. “The multilateral talks, the main accord being pursued by President Barack Obama’s administration, … began with Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the U.S. and Vietnam [and] may expand after the parties invited Canada and Mexico,” the news service notes.